Latest Capital Structure News

CTI Logistics reported modest revenue growth and a strong EBITDA increase in FY25, underpinned by a significant property valuation uplift and strategic capital investments. The company is poised for sustainable growth amid a consolidating freight market.

CTI Logistics Limited has announced a fully franked ordinary dividend of AUD 0.055 per share for the half-year ending June 2025, offering shareholders reinvestment and bonus security plans with attractive discounts.

FortifAI Limited reported a 15% decline in game revenue to $4.3 million for FY2025 but achieved a significant 72% reduction in net loss to $1.99 million, supported by operational cost cuts and a $3.6 million capital raise.

NEXTDC has delivered record FY25 financial results, surpassing revenue and EBITDA guidance while aggressively expanding its data centre footprint across Australia and Asia-Pacific. The company’s strengthened liquidity and strategic investments position it to capitalise on soaring AI and cloud demand.

Glennon Small Companies Limited reported a robust FY25 with a 232.75% jump in net profit and declared final dividends, while strategically resetting its preference shares amid evolving small-cap market dynamics.

Brazilian Critical Minerals Ltd has converted a significant portion of its outstanding debt into equity, issuing over 120 million shares to a key investor, while also raising a modest $50,000 through a new share placement to support working capital.

Mad Paws Holdings reported a $12.27 million loss for FY25, deepening from last year, as it divests its Pet Chemist business and agrees to a $62 million acquisition by Rover Group.

NSX Limited reported a 5.1% rise in revenue to $1.55 million for FY2025, yet its net loss edged up slightly to $4.15 million amid a significant joint venture divestment and ongoing financial uncertainties.

The 2025 annual report for SPDR Core Equity ETFs confirms compliance with accounting standards and provides detailed unitholder data, underscoring the funds' robust governance and market position.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Energy Technologies Limited reported a $11 million net loss for FY2025, reflecting a strategic pivot and ongoing capital challenges. Despite a 37% revenue drop, management highlights operational resilience and plans to stabilise through capital management.